BACKGROUND:Hepatic encephalopathy has a negative effect on patient health-related quality of life (HRQOL). Zinc supplementation has been effective with regard to altered nitrogen metabolism. AIM: To investigate the effectiveness of oral zinc supplementation on hepatic encephalopathy and HRQOL. METHODS:Seventy-nine cirrhotic patients with hepatic encephalopathy were randomized to receive 225 mg of polaprezinc in addition to standard therapies of a protein-restricted diet including branched-chain amino acid and lactulose, or to continue only standard therapies for 6 months. The change of HRQOL by Short Form-36, hepatic encephalopathy grade, laboratory parameters, and neuropsychological (NP) tests were compared at baseline and at 6 months. We also evaluated via multivariate analysis whether zinc supplementation and clinical variables correlated with the changes in physical component scale (PCS) and mental component scale (MCS) between the two visits. RESULTS:Zinc supplementation significantly improved the PCS (P = 0.04), but not the MCS (P = 0.95). Zinc supplementation significantly decreased hepatic encephalopathy grade and blood ammonia levels (P = 0.03 and P = 0.01), and improved Child-Pugh score and NP tests compared with standard therapy (P = 0.04 and P = 0.02). In multivariate analysis, zinc supplementation was significantly associated with improvement in PCS (P = 0.03), whereas it was not significantly associated with change in MCS (P = 0.98). CONCLUSION:Zinc supplementation is effective in hepatic encephalopathy and consequently improves patients HRQOL.
RCT Entities:
BACKGROUND:Hepatic encephalopathy has a negative effect on patient health-related quality of life (HRQOL). Zinc supplementation has been effective with regard to altered nitrogen metabolism. AIM: To investigate the effectiveness of oral zinc supplementation on hepatic encephalopathy and HRQOL. METHODS: Seventy-nine cirrhotic patients with hepatic encephalopathy were randomized to receive 225 mg of polaprezinc in addition to standard therapies of a protein-restricted diet including branched-chain amino acid and lactulose, or to continue only standard therapies for 6 months. The change of HRQOL by Short Form-36, hepatic encephalopathy grade, laboratory parameters, and neuropsychological (NP) tests were compared at baseline and at 6 months. We also evaluated via multivariate analysis whether zinc supplementation and clinical variables correlated with the changes in physical component scale (PCS) and mental component scale (MCS) between the two visits. RESULTS: Zinc supplementation significantly improved the PCS (P = 0.04), but not the MCS (P = 0.95). Zinc supplementation significantly decreased hepatic encephalopathy grade and blood ammonia levels (P = 0.03 and P = 0.01), and improved Child-Pugh score and NP tests compared with standard therapy (P = 0.04 and P = 0.02). In multivariate analysis, zinc supplementation was significantly associated with improvement in PCS (P = 0.03), whereas it was not significantly associated with change in MCS (P = 0.98). CONCLUSION: Zinc supplementation is effective in hepatic encephalopathy and consequently improves patients HRQOL.
Authors: Mohammad K Mohammad; Mohammad K Mohommad; Zhanxiang Zhou; Matthew Cave; Ashutosh Barve; Craig J McClain Journal: Nutr Clin Pract Date: 2012-02 Impact factor: 3.080
Authors: Anatoly V Skalny; Margarita G Skalnaya; Andrei R Grabeklis; Anastasia A Skalnaya; Alexey A Tinkov Journal: Eur J Nutr Date: 2017-11-24 Impact factor: 5.614
Authors: Shreya Sengupta; Kristen Wroblewski; Andrew Aronsohn; Nancy Reau; K Gautham Reddy; Donald Jensen; Helen Te Journal: Dig Dis Sci Date: 2015-03-06 Impact factor: 3.199